Reaction
Immune-Mediated Arthritis reporting signals
As of the last recalculation, Immune-Mediated Arthritis appears in 365 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 191.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 180 | 191.5 | 191.8 |
| Nivolumab | 130 | 118.6 | 118.7 |
| Ipilimumab | 71 | 116.2 | 116.4 |
| Pemetrexed | 22 | 62.2 | 62.3 |
| Pemetrexed Disodium | 24 | 38.4 | 38.4 |
| Durvalumab | 13 | 37.7 | 37.8 |
| Carboplatin | 60 | 32.0 | 32.1 |
| Axitinib | 8 | 23.9 | 23.9 |
| Atezolizumab | 15 | 22.9 | 22.9 |